| __timestamp | Biogen Inc. | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 4473654 |
| Thursday, January 1, 2015 | 2113100000 | 8597010 |
| Friday, January 1, 2016 | 1947900000 | 7910260 |
| Sunday, January 1, 2017 | 1935500000 | 7304399 |
| Monday, January 1, 2018 | 2106300000 | 15875961 |
| Tuesday, January 1, 2019 | 2374700000 | 36881187 |
| Wednesday, January 1, 2020 | 2504500000 | 44233754 |
| Friday, January 1, 2021 | 2674300000 | 49628000 |
| Saturday, January 1, 2022 | 2403600000 | 58183000 |
| Sunday, January 1, 2023 | 2549700000 | 133710000 |
| Monday, January 1, 2024 | 2403700000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Biogen Inc. and Catalyst Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Biogen, a leader in biotechnology, consistently allocated a significant portion of its budget to SG&A, peaking in 2021 with a 38% increase from 2017. This reflects its aggressive market expansion and strategic investments. In contrast, Catalyst Pharmaceuticals, a smaller player, demonstrated a remarkable 2,887% surge in SG&A expenses over the same period, highlighting its rapid growth and increased market presence. By 2023, Catalyst's SG&A expenses reached 13.4 million, a testament to its ambitious scaling efforts. These trends underscore the diverse financial strategies within the pharmaceutical sector, offering insights into how companies prioritize operational and market expansion.
Operational Costs Compared: SG&A Analysis of AbbVie Inc. and Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Catalyst Pharmaceuticals, Inc.
Walgreens Boots Alliance, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.